We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
29 October 2015
The Competition Protection Agency is resuming increased levels of activity. It recently initiated formal proceedings against GlaxoSmithKline (GSK), ARC Nepremičnine doo and GAPS doo, on the basis of a distribution agreement relating to pharmaceutical products.(1)
As the distribution agreement could interfere with trade within Slovenia as well as with trade between EU member states, the agency will assess the potential infringement based on both Article 6 of the Prevention of Restriction of Competition Act and Article 101 of the Treaty of the Functioning of the European Union.
In the absence of local secondary legislation and guidelines on the implementation of Article 6 of the Prevention of Restriction of Competition Act, the agency will likely rely on the EU Exemption for Vertical Supply and Distribution Agreements Regulation (330/2010)(2) and the adjacent Guidelines on Vertical Restraints,(3) as both include provisions and guidance for assessing agreements which could restrict sales on a territorial or customer-group basis.
In its July 29 2015 decision to initiate formal proceedings, the agency found reasonable grounds to believe that the distribution agreement restricts competition by object, as it restricts the territory into which and the customers to which ARC and GAPS may sell GSK's products. The specific agreement regulates distribution of GSK's oral care products and prohibits both companies from either actively or passively selling products within the Slovenian and EU market without supervision by and prior authorisation from GSK.
Along with this decision, the agency requested from the public any information relating to:
The procedural rules of the Prevention of Restriction of Competition Act provide that the agency must put forward all of its allegations in a statement of objections. However, the rules do not prescribe the timeframe within which this should be done.
This is not the first proceeding that the agency has conducted in the pharmaceutical market. In September 2010 a proceeding against five distributors of pharmaceuticals that were active on the Slovenian market was initiated, resulting in a decision that four of the undertakings had breached Article 6 of the Prevention of Restriction of Competition Act and Article 101 the Treaty of the Functioning of the European Union. In this respect, a separate misdemeanour proceeding must now take place, which may result in the imposition of a fine of up to 10% of the implicated undertakings' annual turnover in the preceding business year.
Although there is no official prioritisation of industries when it comes to scrutiny of the market, it seems that pharmaceutical companies are among those that most often find themselves under the spotlight of the agency.
For further information on this topic please contact Eva Škufca at Schoenherr by telephone (+386 1 200 09 80) or email (firstname.lastname@example.org). The Schoenherr website can be accessed at www.schoenherr.eu.
(3) European Commission, "Guidelines on Vertical Restraints" (2010/C 130/01), available at www.eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:130:0001:0046:EN:PDF.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.